TrialBreast cancer research : BCR2025

High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy.

Amadeo M Parissenti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.